Navigation Links
Aduromed Files Patent Application to Cover Proprietary New Standard for Containerized, Turnkey Solution
Date:12/2/2008

BETHEL, Conn., Dec. 2 /PRNewswire-FirstCall/ -- Aduromed Industries, Inc. (OTC Bulletin Board: ADRM), a leading provider of medical waste treatment systems, today announced that it successfully filed a U.S. patent on November 24, 2008 to protect the Company's proprietary technology for its new standard, containerized MedClean Systems that provide a turnkey solution for onsite regulated medical waste sterilization and volume reduction.

The patent application, entitled "Containerized Medical Waste Treatment System and Related Method," focuses on the design and configuration of Aduromed's new standard, containerized MedClean Systems.

"The Aduromed team has invested significant time and effort into evolving its operating model to meet the business and regulatory demands of the health care institutions it targets," commented Scott Grisanti, President and Chief Executive Officer of Aduromed. "The resultant solutions have the potential to produce a sustainable competitive advantage, and we have taken significant steps to protect this intellectual property through this patent filing. The patent pre-stages market introduction of the MedClean series of containerized systems that are designed to make it easier for health care institutions to implement onsite processing solutions for regulated medical waste that reduce costs, mitigate risk, and enhance Green profiles."

The patent application also covers the specific protocol employed to accomplish sterilization in the company's autoclave subsystem. The protocol implements a sequence of differential heating and vacuum cycles designed to optimize efficacy and balance cycle time.

"The treatment protocol included in the patent is the result of research conducted with customers and industry experts that has yielded the most extensive body of work in the industry," added Mr. Grisanti. "This tested and validated protocol is a key component of our propriet
'/>"/>

SOURCE Aduromed Industries, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Aduromed Closes Restructuring and Raises $3.8 Million of New Equity Capital
2. Alvarado Hospital Files Countersuit Against Blue Shield
3. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
4. Pharsight Files Application for Nasdaq Capital Market Listing
5. Gentiva(R) Health Services Files Universal Shelf Registration Statement
6. Paramount Acquisition Corp. Files Amendment to Preliminary Proxy Statement for Proposed Acquisition of Chem Rx
7. CIGNA Behavioral Health Offers Members Online Provider Profiles
8. American Media Operations, Inc. Files Form 10-Q For First Quarter 2007
9. RxElite Files Registration Statement with Securities and Exchange Commission
10. Dynamic Files Articles of Merger; Notifies Nasdaq of Merger with GeoPharma
11. Mach One Corporation Files its Form SB-2 with the SEC
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 3New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 2New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 3New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10VAs Health System Top Employer for AARP 58061 1VAs Health System Top Employer for AARP 58061 2Historic gene therapy trial to treat Alzheimers disease underway at Georgetown 58056 1Historic gene therapy trial to treat Alzheimers disease underway at Georgetown 58056 2Journalists invited to Darwin Chicago 2009 conference Oct 29 31 10039 1